| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 20 | 2025 | 477 | 3.580 |
Why?
|
| Immunogenicity, Vaccine | 19 | 2026 | 115 | 3.340 |
Why?
|
| Influenza, Human | 19 | 2025 | 671 | 3.000 |
Why?
|
| Antibodies, Viral | 35 | 2026 | 1129 | 2.720 |
Why?
|
| Antibodies, Neutralizing | 24 | 2026 | 496 | 2.280 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 7 | 2025 | 27 | 2.150 |
Why?
|
| Immunization, Secondary | 12 | 2025 | 112 | 1.980 |
Why?
|
| Vaccines | 7 | 2025 | 379 | 1.930 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 2 | 2020 | 10 | 1.270 |
Why?
|
| HIV Infections | 10 | 2025 | 1952 | 1.240 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 5 | 2021 | 58 | 1.160 |
Why?
|
| Adjuvants, Immunologic | 12 | 2025 | 373 | 1.150 |
Why?
|
| Vaccines, Inactivated | 11 | 2025 | 145 | 1.110 |
Why?
|
| Respiratory Tract Infections | 3 | 2026 | 275 | 1.060 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2013 | 408 | 0.940 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2025 | 13 | 0.920 |
Why?
|
| Histoplasmosis | 1 | 2025 | 54 | 0.890 |
Why?
|
| Hemagglutination Inhibition Tests | 14 | 2025 | 109 | 0.890 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2025 | 71 | 0.890 |
Why?
|
| Zika Virus Infection | 5 | 2024 | 173 | 0.830 |
Why?
|
| Vaccination | 17 | 2026 | 993 | 0.820 |
Why?
|
| Tuberculosis | 5 | 2014 | 535 | 0.820 |
Why?
|
| Adult | 59 | 2026 | 30051 | 0.820 |
Why?
|
| Humans | 106 | 2026 | 124973 | 0.820 |
Why?
|
| Polysorbates | 7 | 2025 | 25 | 0.760 |
Why?
|
| Squalene | 7 | 2025 | 25 | 0.760 |
Why?
|
| Bacteremia | 2 | 2019 | 417 | 0.760 |
Why?
|
| Pandemics | 5 | 2025 | 1120 | 0.750 |
Why?
|
| Zika Virus | 5 | 2024 | 149 | 0.710 |
Why?
|
| Microcephaly | 2 | 2024 | 343 | 0.700 |
Why?
|
| Middle Aged | 45 | 2026 | 27074 | 0.670 |
Why?
|
| Influenza in Birds | 1 | 2020 | 24 | 0.650 |
Why?
|
| Male | 60 | 2026 | 61670 | 0.620 |
Why?
|
| Clostridium septicum | 1 | 2019 | 2 | 0.620 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2019 | 3 | 0.620 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 194 | 0.610 |
Why?
|
| Viral Vaccines | 4 | 2026 | 313 | 0.600 |
Why?
|
| Antitubercular Agents | 4 | 2013 | 263 | 0.600 |
Why?
|
| Population Surveillance | 5 | 2013 | 393 | 0.590 |
Why?
|
| Young Adult | 26 | 2026 | 9535 | 0.580 |
Why?
|
| Encephalitis | 1 | 2019 | 117 | 0.580 |
Why?
|
| Viral Load | 3 | 2024 | 398 | 0.570 |
Why?
|
| Hemagglutinins | 2 | 2021 | 25 | 0.550 |
Why?
|
| Acanthamoeba | 1 | 2017 | 10 | 0.540 |
Why?
|
| Amebiasis | 1 | 2017 | 11 | 0.540 |
Why?
|
| Female | 59 | 2026 | 67493 | 0.540 |
Why?
|
| Immunization Schedule | 7 | 2025 | 102 | 0.530 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 41 | 0.530 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 425 | 0.510 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 236 | 0.510 |
Why?
|
| Anthrax Vaccines | 5 | 2016 | 25 | 0.490 |
Why?
|
| Clostridium Infections | 1 | 2019 | 242 | 0.480 |
Why?
|
| Smallpox Vaccine | 3 | 2025 | 38 | 0.480 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 382 | 0.480 |
Why?
|
| Spike Glycoprotein, Coronavirus | 5 | 2024 | 199 | 0.480 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 280 | 0.470 |
Why?
|
| RNA, Viral | 3 | 2024 | 508 | 0.460 |
Why?
|
| Double-Blind Method | 16 | 2026 | 1587 | 0.460 |
Why?
|
| Francisella tularensis | 2 | 2017 | 16 | 0.440 |
Why?
|
| Seizures | 1 | 2019 | 854 | 0.440 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 101 | 0.430 |
Why?
|
| Guatemala | 6 | 2024 | 64 | 0.430 |
Why?
|
| Adolescent | 31 | 2026 | 19921 | 0.420 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2013 | 185 | 0.410 |
Why?
|
| Disease Outbreaks | 2 | 2008 | 305 | 0.410 |
Why?
|
| Clinical Trials as Topic | 6 | 2025 | 1081 | 0.390 |
Why?
|
| Adenosine Monophosphate | 2 | 2024 | 42 | 0.390 |
Why?
|
| Aged | 22 | 2026 | 19830 | 0.380 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 953 | 0.380 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2005 | 227 | 0.370 |
Why?
|
| Antigens, Viral | 2 | 2024 | 391 | 0.370 |
Why?
|
| Alanine | 2 | 2024 | 157 | 0.370 |
Why?
|
| Antibodies, Bacterial | 7 | 2017 | 400 | 0.360 |
Why?
|
| Urban Population | 1 | 2013 | 234 | 0.360 |
Why?
|
| Injections, Intradermal | 5 | 2025 | 28 | 0.360 |
Why?
|
| Dengue | 2 | 2024 | 120 | 0.360 |
Why?
|
| Aza Compounds | 1 | 2011 | 14 | 0.350 |
Why?
|
| Immunoglobulin G | 10 | 2025 | 742 | 0.350 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2026 | 73 | 0.330 |
Why?
|
| Malaria Vaccines | 1 | 2010 | 17 | 0.330 |
Why?
|
| Quinolines | 1 | 2011 | 110 | 0.330 |
Why?
|
| Malaria, Falciparum | 1 | 2010 | 49 | 0.330 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 69 | 0.320 |
Why?
|
| RNA, Messenger | 4 | 2023 | 2539 | 0.310 |
Why?
|
| Case-Control Studies | 6 | 2025 | 3254 | 0.310 |
Why?
|
| Orthomyxoviridae | 2 | 2011 | 50 | 0.310 |
Why?
|
| Protozoan Proteins | 1 | 2010 | 122 | 0.310 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1340 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2024 | 1165 | 0.290 |
Why?
|
| Anthrax | 3 | 2014 | 29 | 0.290 |
Why?
|
| Treatment Outcome | 11 | 2025 | 12233 | 0.280 |
Why?
|
| Child Development | 2 | 2021 | 267 | 0.280 |
Why?
|
| Brain | 1 | 2019 | 3020 | 0.280 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2007 | 11 | 0.270 |
Why?
|
| Antiviral Agents | 2 | 2024 | 776 | 0.260 |
Why?
|
| Injections, Intramuscular | 9 | 2025 | 181 | 0.260 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2024 | 821 | 0.260 |
Why?
|
| Vaccines, Synthetic | 6 | 2022 | 312 | 0.250 |
Why?
|
| Organophosphonates | 1 | 2006 | 21 | 0.250 |
Why?
|
| United States | 10 | 2025 | 11095 | 0.250 |
Why?
|
| Injections, Subcutaneous | 6 | 2025 | 126 | 0.250 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 33 | 0.240 |
Why?
|
| Chikungunya virus | 1 | 2026 | 27 | 0.240 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2025 | 8 | 0.240 |
Why?
|
| Chikungunya Fever | 1 | 2026 | 32 | 0.240 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 786 | 0.240 |
Why?
|
| Texas | 8 | 2013 | 3509 | 0.230 |
Why?
|
| Immunity, Mucosal | 1 | 2025 | 83 | 0.230 |
Why?
|
| Adenine | 1 | 2006 | 105 | 0.230 |
Why?
|
| Placebos | 5 | 2016 | 221 | 0.230 |
Why?
|
| Histoplasma | 1 | 2025 | 37 | 0.230 |
Why?
|
| Administration, Mucosal | 1 | 2025 | 1 | 0.230 |
Why?
|
| Infant | 9 | 2024 | 12733 | 0.230 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2005 | 81 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 222 | 0.220 |
Why?
|
| Patient Acuity | 2 | 2021 | 62 | 0.220 |
Why?
|
| Creatinine | 1 | 2006 | 359 | 0.220 |
Why?
|
| Azetidines | 2 | 2022 | 59 | 0.210 |
Why?
|
| Research Design | 2 | 2026 | 679 | 0.210 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 4 | 0.210 |
Why?
|
| Single-Blind Method | 2 | 2021 | 229 | 0.210 |
Why?
|
| Purines | 2 | 2022 | 109 | 0.210 |
Why?
|
| Area Under Curve | 1 | 2024 | 291 | 0.210 |
Why?
|
| Dengue Virus | 2 | 2024 | 131 | 0.210 |
Why?
|
| Nasopharynx | 1 | 2024 | 85 | 0.210 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2017 | 56 | 0.200 |
Why?
|
| Schistosomiasis mansoni | 1 | 2023 | 24 | 0.200 |
Why?
|
| Incidence | 4 | 2021 | 3157 | 0.200 |
Why?
|
| Water Microbiology | 1 | 2002 | 26 | 0.190 |
Why?
|
| Water Supply | 1 | 2002 | 25 | 0.190 |
Why?
|
| Antifungal Agents | 1 | 2025 | 301 | 0.190 |
Why?
|
| Aedes | 1 | 2023 | 101 | 0.190 |
Why?
|
| Azithromycin | 1 | 2022 | 41 | 0.190 |
Why?
|
| Vomiting | 1 | 2023 | 98 | 0.190 |
Why?
|
| Mycobacterium | 1 | 2002 | 30 | 0.190 |
Why?
|
| Vancomycin | 1 | 2024 | 221 | 0.190 |
Why?
|
| Mycobacterium Infections | 1 | 2002 | 32 | 0.190 |
Why?
|
| Cough | 1 | 2023 | 92 | 0.190 |
Why?
|
| Vaccinia virus | 2 | 2025 | 50 | 0.190 |
Why?
|
| Sulfonamides | 2 | 2022 | 266 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2026 | 5042 | 0.190 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2021 | 13 | 0.180 |
Why?
|
| Growth Disorders | 1 | 2023 | 192 | 0.180 |
Why?
|
| Healthy Volunteers | 4 | 2026 | 146 | 0.180 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 59 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2022 | 310 | 0.180 |
Why?
|
| Vaccines, Attenuated | 3 | 2017 | 173 | 0.180 |
Why?
|
| Diarrhea | 1 | 2023 | 304 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 6515 | 0.170 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 45 | 0.170 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2024 | 471 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 779 | 0.170 |
Why?
|
| DNA, Bacterial | 3 | 2011 | 481 | 0.170 |
Why?
|
| Emigration and Immigration | 1 | 2000 | 81 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2024 | 6133 | 0.160 |
Why?
|
| Critical Illness | 1 | 2024 | 598 | 0.160 |
Why?
|
| Occupational Health | 1 | 2020 | 46 | 0.160 |
Why?
|
| Mycobacterium avium Complex | 2 | 2021 | 20 | 0.160 |
Why?
|
| Birds | 1 | 2020 | 84 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 170 | 0.160 |
Why?
|
| Motor Skills | 1 | 2020 | 77 | 0.160 |
Why?
|
| Lipid A | 1 | 2019 | 22 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2025 | 522 | 0.160 |
Why?
|
| Language Tests | 1 | 2019 | 24 | 0.160 |
Why?
|
| Cytokines | 3 | 2020 | 1306 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2006 | 597 | 0.150 |
Why?
|
| Cross Infection | 1 | 2002 | 326 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 522 | 0.150 |
Why?
|
| Schistosomiasis | 1 | 2019 | 52 | 0.150 |
Why?
|
| Glucosides | 1 | 2019 | 49 | 0.150 |
Why?
|
| Antibodies, Helminth | 1 | 2019 | 128 | 0.150 |
Why?
|
| Body Fluids | 1 | 2019 | 46 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 88 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 1234 | 0.140 |
Why?
|
| Workflow | 1 | 2019 | 132 | 0.140 |
Why?
|
| Language Development Disorders | 1 | 2019 | 176 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 464 | 0.140 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 2487 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 980 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2021 | 390 | 0.130 |
Why?
|
| Influenza B virus | 2 | 2023 | 98 | 0.130 |
Why?
|
| Child, Preschool | 8 | 2024 | 14341 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 280 | 0.130 |
Why?
|
| Immunoglobulin A | 2 | 2025 | 203 | 0.130 |
Why?
|
| Child | 7 | 2024 | 25038 | 0.130 |
Why?
|
| Learning | 1 | 2020 | 355 | 0.130 |
Why?
|
| Drug Carriers | 1 | 2017 | 114 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 174 | 0.120 |
Why?
|
| Caregivers | 1 | 2021 | 544 | 0.120 |
Why?
|
| Coccidioidomycosis | 1 | 2015 | 9 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2022 | 4852 | 0.120 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 277 | 0.120 |
Why?
|
| Cholecystitis | 1 | 2015 | 19 | 0.120 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2015 | 24 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 523 | 0.120 |
Why?
|
| Biomarkers | 1 | 2024 | 3115 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 379 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 357 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 370 | 0.110 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2014 | 10 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 330 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2015 | 132 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 3202 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 261 | 0.100 |
Why?
|
| Animals | 7 | 2023 | 32914 | 0.100 |
Why?
|
| Molecular Epidemiology | 2 | 2005 | 142 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 183 | 0.100 |
Why?
|
| Risk Factors | 4 | 2013 | 10275 | 0.100 |
Why?
|
| Psychometrics | 3 | 2021 | 652 | 0.090 |
Why?
|
| Bacillus anthracis | 2 | 2009 | 38 | 0.090 |
Why?
|
| Prevalence | 2 | 2011 | 2560 | 0.090 |
Why?
|
| China | 2 | 2024 | 271 | 0.090 |
Why?
|
| Mortality | 1 | 2013 | 244 | 0.090 |
Why?
|
| Erythema Infectiosum | 1 | 2011 | 5 | 0.090 |
Why?
|
| Schistosoma mansoni | 2 | 2023 | 24 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 337 | 0.090 |
Why?
|
| Parvovirus B19, Human | 1 | 2011 | 25 | 0.090 |
Why?
|
| Coinfection | 1 | 2013 | 182 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 227 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 32 | 0.090 |
Why?
|
| Ofloxacin | 1 | 2011 | 31 | 0.090 |
Why?
|
| Aluminum Compounds | 1 | 2010 | 16 | 0.080 |
Why?
|
| alpha-Tocopherol | 2 | 2024 | 36 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 97 | 0.080 |
Why?
|
| Human Experimentation | 1 | 2010 | 32 | 0.080 |
Why?
|
| Exanthema | 1 | 2011 | 73 | 0.080 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 81 | 0.080 |
Why?
|
| Rural Population | 2 | 2024 | 244 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2025 | 262 | 0.080 |
Why?
|
| Plasmodium falciparum | 1 | 2010 | 73 | 0.080 |
Why?
|
| Phosphates | 1 | 2010 | 108 | 0.080 |
Why?
|
| Pregnancy | 4 | 2024 | 7327 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2024 | 264 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2025 | 16569 | 0.080 |
Why?
|
| Influenza A virus | 1 | 2010 | 146 | 0.080 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 44 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2846 | 0.080 |
Why?
|
| Logistic Models | 2 | 2005 | 1714 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 206 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 730 | 0.070 |
Why?
|
| HIV-1 | 1 | 2012 | 468 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3555 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2013 | 0.070 |
Why?
|
| Europe | 1 | 2008 | 349 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 277 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2009 | 508 | 0.070 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2006 | 9 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3588 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 1278 | 0.060 |
Why?
|
| Measles virus | 1 | 2026 | 16 | 0.060 |
Why?
|
| Research | 1 | 2008 | 254 | 0.060 |
Why?
|
| Tenofovir | 1 | 2006 | 23 | 0.060 |
Why?
|
| Neutralization Tests | 2 | 2017 | 225 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2020 | 953 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 909 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 1719 | 0.060 |
Why?
|
| Immunity, Humoral | 1 | 2025 | 74 | 0.060 |
Why?
|
| Cities | 1 | 2004 | 46 | 0.050 |
Why?
|
| Urban Health | 1 | 2004 | 74 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2004 | 70 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2023 | 12 | 0.050 |
Why?
|
| Carrier State | 1 | 2004 | 73 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 2 | 2000 | 194 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 293 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 39 | 0.050 |
Why?
|
| Aluminum Hydroxide | 1 | 2023 | 38 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2023 | 130 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 132 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 233 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 675 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 296 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1333 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 275 | 0.050 |
Why?
|
| Protozoan Vaccines | 1 | 2023 | 98 | 0.050 |
Why?
|
| Bacterial Toxins | 2 | 2016 | 170 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 134 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 5987 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2002 | 98 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 306 | 0.040 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2021 | 25 | 0.040 |
Why?
|
| Antigens, Bacterial | 2 | 2016 | 308 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 865 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 259 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 27 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1485 | 0.040 |
Why?
|
| Ethambutol | 1 | 2000 | 5 | 0.040 |
Why?
|
| Recurrence | 1 | 2004 | 1387 | 0.040 |
Why?
|
| Translations | 1 | 2020 | 17 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8324 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 89 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 322 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2000 | 124 | 0.040 |
Why?
|
| Age Distribution | 1 | 2000 | 413 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2000 | 407 | 0.040 |
Why?
|
| Translating | 1 | 2019 | 30 | 0.040 |
Why?
|
| Rural Health | 1 | 2019 | 39 | 0.040 |
Why?
|
| Child Language | 1 | 2019 | 28 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 49 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 541 | 0.040 |
Why?
|
| Semen | 1 | 2019 | 80 | 0.040 |
Why?
|
| Antigens, Helminth | 1 | 2019 | 185 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 127 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 363 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2017 | 8 | 0.030 |
Why?
|
| Seroconversion | 1 | 2017 | 15 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 66 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 482 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1138 | 0.030 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 22 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 2017 | 42 | 0.030 |
Why?
|
| Vagina | 1 | 2019 | 198 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 3636 | 0.030 |
Why?
|
| Baculoviridae | 1 | 2017 | 40 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2017 | 99 | 0.030 |
Why?
|
| Emulsions | 1 | 2017 | 69 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 960 | 0.030 |
Why?
|
| Milk, Human | 1 | 2019 | 307 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1593 | 0.030 |
Why?
|
| Hemagglutination, Viral | 1 | 2015 | 9 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 297 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 48 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2004 | 3389 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1678 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 219 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2015 | 161 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 258 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1799 | 0.020 |
Why?
|
| Pharynx | 1 | 2011 | 64 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 3877 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 518 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2011 | 143 | 0.020 |
Why?
|
| Nose | 1 | 2011 | 89 | 0.020 |
Why?
|
| New York | 1 | 2009 | 68 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2009 | 81 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 148 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2749 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 632 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 17411 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 208 | 0.020 |
Why?
|
| Dinucleotide Repeats | 1 | 2002 | 6 | 0.010 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2000 | 3 | 0.010 |
Why?
|
| Pentosyltransferases | 1 | 2000 | 12 | 0.010 |
Why?
|
| Operon | 1 | 2000 | 48 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2002 | 389 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 779 | 0.010 |
Why?
|